Roche has unveiled promising Phase Ib/IIa trial results suggesting its “brain shuttle” Alzheimer’s disease candidate trontinemab could be safer and more effective than approved therapies, and will begin a Phase III study later this year.
Roche needed to be convinced that trontinemab could do better than the disappointing profiles of approved beta-amyloid targeting antibodies, Biogen/Eisai’s Leqembi (lecanemab) and Eli Lilly’s Kisunla (donanemab).
Key Takeaways
- 81% of participants reached 'amyloid negative' status after 28 weeks - further and faster than seen in longer rival Phase III studies.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
